Levonorgestrel
- Levonorgestrel
- Levonorgestrel (USAN:USP:INN:BAN)
- 797-63-7
- Liletta
- Skyla
- Levonorgestrel
- Levonorgestrel (USAN:USP:INN:BAN)
- 797-63-7
- Liletta
- Skyla
- 13-Ethyl-17-hydroxy-18,19-dinor-17alpha- pregn-4-en-20-yn-3-one
- 5W7SIA7YZW
- Fallback Solo
- Kyleena
- Levonorgestrelum
- Plan B One-Step
- 17-Ethynyl-18-methyl-19-nortestosterone
- 18-Methylnorethisterone
- Athentia Next
- Her Style
- Jadelle
- Opcicon One-Step
- (-)-13-ETHYL-17-HYDROXY-18,19-DINOR-17alpha-PREGN-4-EN-20-YN-3-ONE
- (17alpha)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one
- 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one
- 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one
- 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol
- 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one
- 17alpha-Ethynyl-18-homo-19-nortestosterone
- 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(-)-
- 18-Methyl-17-alpha-ethynyl-19-nortestosterone
- D-Norgestrel
- Norplant system in plastic container
- Wy-5104
- (-)-Norgestrel
- 13-Ethyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one
- 13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one
- 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
- 17-alpha-Ethynyl-13-ethyl-19-nortestosterone
- 212-349-8
- AfterPill
- AfterPlan
- Aftera
- BAY86-5028
- CHEBI:6443
- Curae
- D-(-)-Norgestrel
- EContra One-Step
- Econ Morning After
- Emergency Contraceptive
- Fem Choice morning after
- ITHAPPENZ MORNING AFTER
- Julie
- LEADER Emergency Contraceptive Levonorgestrel
- Levonorgestrel Tablet, 1.5 mg
- Levonova
- Morning After
- My Choice TM
- My Way
- New Day
- Next Choice
- Next Choice One Dose
- Option 2
- Optionelle
- PostDay One-Step
- SheWise
- Stix Restart
- Take Action
- basic care levonorgestrel
- d(-)-Norgestrel
- (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta(a) phenanthren-3-one
- 13-Ethyl-17-ethynyl-17beta-hydroxy-4-gonen-3-one
- 13alpha-ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
- 13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
- 17-beta-Hydroxy-18-methyl-19-nor-17-alpha-pregn-4-en-20-yn-3-one
- 17alpha-Ethynyl-13-ethyl-19-nortestosterone
- 17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one
- 18,19-Dinor-17-alpha-pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-
- 18-Methylnorethindrone
- 19-Nortestosterone, 17-ethynyl-18-methyl-
- AFIRMELLE COMPONENT LEVONORGESTREL
- ALESSE COMPONENT LEVONORGESTREL
- ALTAVERA COMPONENT LEVONORGESTREL
- AVIANE COMPONENT LEVONORGESTREL
- After Banger
- BAY 86-5028
- BRN 2391114
- CCRIS 6525
- CLIMARA PRO COMPONENT LEVONORGESTREL
- D Norgestrel
- D-l-Norgestrel
- DTXCID1016496
- DTXSID3036496
- E-Gen-C
- EINECS 212-349-8
- ELIFEMME COMPONENT LEVONORGESTREL
- ENPRESSE COMPONENT LEVONORGESTREL
- Empowered Choice
- G03AC03
- G03AD01
- HSDB 6483
- IMPLANT WITH LEVONORGESTREL
- INTROVALE COMPONENT LEVONORGESTREL
- Intrauterine levonorgestrel
- KURVELO COMPONENT LEVONORGESTREL
- KYLEENA COMPONENT LEVONORGESTREL
- LESSINA COMPONENT LEVONORGESTREL
- LEVLITE COMPONENT LEVONORGESTREL
- LEVONEST COMPONENT LEVONORGESTREL
- LEVONORGESTREL (EP MONOGRAPH)
- LEVONORGESTREL (MART.)
- LEVONORGESTREL (USP IMPURITY)
- LEVONORGESTREL (USP MONOGRAPH)
- LEVONORGESTREL (USP-RS)
- LEVONORGESTREL COMPONENT OF ALESSE
- LEVONORGESTREL COMPONENT OF ALTAVERA
- LEVONORGESTREL COMPONENT OF CLIMARA PRO
- LEVONORGESTREL COMPONENT OF INTROVALE
- LEVONORGESTREL COMPONENT OF KYLEENA
- LEVONORGESTREL COMPONENT OF LEVLITE
- LEVONORGESTREL COMPONENT OF LEVONEST
- LEVONORGESTREL COMPONENT OF LOSEASONIQUE
- LEVONORGESTREL COMPONENT OF LYBREL
- LEVONORGESTREL COMPONENT OF OPCICON ONE-STEP
- LEVONORGESTREL COMPONENT OF PREVEN
- LEVONORGESTREL COMPONENT OF QUASENSE
- LEVONORGESTREL COMPONENT OF SEASONALE
- LEVONORGESTREL COMPONENT OF SEASONIQUE
- LEVONORGESTREL COMPONENT OF SETLAKIN
- LEVONORGESTREL COMPONENT OF TWIRLA
- LEVORA COMPONENT LEVONORGESTREL
- LNG-IUS
- LOSEASONIQUE COMPONENT LEVONORGESTREL
- LYBREL COMPONENT LEVONORGESTREL
- Levlen ED
- Levogel
- Levonelle
- Levonorgestrel 1.5 mg
- Levonorgestrel implant
- Levonorgestrelum (INN-Latin)
- Levora-21
- Levora-28
- Levosert
- Logynon ED
- MARLISSA COMPONENT LEVONORGESTREL
- MYZILRA COMPONENT LEVONORGESTREL
- Microgest ED
- Microgyn
- Microgynon 21
- Microgynon 28
- Microgynon 30 ED
- Microgynon CD
- Microlution
- Microluton
- Monofeme 28
- NORDETTE COMPONENT LEVONORGESTREL
- NORGESTIMATE IMPURITY B (EP IMPURITY)
- NORGESTREL (-)-FORM
- NORGESTREL, (-)-
- NSC 744007
- NSC 759653
- NSC-744007
- Neogynon 21
- Nordet
- Nordette 21
- Nordette 28
- Norplant II
- OPCICON ONE-STEP COMPONENT LEVONORGESTREL
- ORSYTHIA COMPONENT LEVONORGESTREL
- Oral levonorgestrel
- Ovoplex 30-150
- Ovral-Lo
- Ovranette
- PLASTIC IUD WITH LEVONORGESTREL
- PORTIA COMPONENT LEVONORGESTREL
- PREVEN COMPONENT LEVONORGESTREL
- Plan B One Step
- Preven
- QUARTETTE COMPONENT LEVONORGESTREL
- QUASENSE COMPONENT LEVONORGESTREL
- React
- Rigevidon 21+7
- SEASONALE COMPONENT LEVONORGESTREL
- SEASONIQUE COMPONENT LEVONORGESTREL
- SETLAKIN COMPONENT LEVONORGESTREL
- Stediril 30
- TRIPHASIL COMPONENT LEVONORGESTREL
- TRIVORA COMPONENT LEVONORGESTREL
- TWIRLA COMPONENT LEVONORGESTREL
- Tri-Levlen 21
- Triagynon
- Triciclor
- Trifeme 28
- Trigoa
- Trinordiol 21
- Trinordiol 28
- Triphasil 21
- Triphasil 28
- Triquilar ED
- UNII-5W7SIA7YZW
- VIENVA COMPONENT LEVONORGESTREL
- l Norgestrel
- levonorgestrel|norgestrel
313.2162 100
109.0648 24.16
245.19 12.79
91.0542 9.93
83.0491 9.61
149.0972 100
133.066 44.40
119.0503 4.80
277.1607 0.17
- Norgestrel (broader)
- Estradiol; levonorgestrel (component of)
- Ethinyl estradiol; levonorgestrel; ferrous fumarate (component of)
G - Genito urinary system and sex hormones
G03 - Sex hormones and modulators of the genital system
G03A - Hormonal contraceptives for systemic use
G03AC - Progestogens
G03AC03 - Levonorgestrel
G - Genito urinary system and sex hormones
G03 - Sex hormones and modulators of the genital system
G03A - Hormonal contraceptives for systemic use
G03AD - Emergency contraceptives
G03AD01 - Levonorgestrel
H302 (20.5%): Harmful if swallowed [Warning Acute toxicity, oral]
H312 (62.5%): Harmful in contact with skin [Warning Acute toxicity, dermal]
H332 (62.5%): Harmful if inhaled [Warning Acute toxicity, inhalation]
H351 (97.7%): Suspected of causing cancer [Warning Carcinogenicity]
H360 (95.5%): May damage fertility or the unborn child [Danger Reproductive toxicity]
H362 (30.7%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]
P203, P260, P261, P263, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P318, P321, P330, P362+P364, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 88 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Acute Tox. 4 (20.5%)
Acute Tox. 4 (62.5%)
Acute Tox. 4 (62.5%)
Carc. 2 (97.7%)
Repr. 1A (95.5%)
Lact. (30.7%)
Hazard Traits - Reproductive Toxicity
Authoritative List - Prop 65
Report - regardless of intended function of ingredient in the product
IMAP assessments - 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17.alpha.)-: Environment tier I assessment
IMAP assessments - 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17.alpha.)-: Human health tier I assessment
M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007
M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
◉ Summary of Use during Lactation
This record contains information specific to the levonorgestrel intrauterine device (IUD). Although nonhormonal methods are preferred during breastfeeding, progestin-only contraceptives such as levonorgestrel are considered the hormonal contraceptives of choice during lactation. Fair quality evidence indicates that levonorgestrel does not adversely affect the composition of milk, the growth and development of the infant or the milk supply. Expert opinion and a metanalysis hold that the risks of progestin-only contraceptive products usually are acceptable for nursing mothers at any time postpartum. There are no reports of adverse effects in breastfed infants with maternal use of progestin-only contraceptives. Low quality evidence indicates that there may be no difference in breastfeeding rates at 6 months between immediate and delayed insertion of progestin-releasing IUDs. Some evidence indicates that progestin-only contraceptives may offer protection against bone mineral density loss during lactation, or at least do not exacerbate it.
The World Health Association recommends that progestin-only intrauterine devices (IUDs) can be inserted before 48 hours postpartum and after 4 weeks postpartum, but should not be inserted between 48 hours and 4 weeks postpartum. Other guidelines and product labeling consider delayed postpartum insertion acceptable if immediate insertion is not feasible. Four small, randomized studies on this point differed in their outcomes. Three found that early insertion did not adversely affect breastfeeding, and the other found that immediate IUD insertion markedly reduced the breastfeeding rate at 6 months postpartum. A meta-analysis found that the risk of expulsion was no greater in breastfeeding mothers. More recent prospective studies found an increase in the risk of expulsion of intrauterine devices with breastfeeding, while a large retrospective study found a 29% lower risk of expulsion in breastfeeding women. The American College of Obstetrics and Gynecology recommends that women be counseled that immediate postpartum insertion may have a higher expulsion rate than later insertion.
◉ Effects in Breastfed Infants
One study found serum thyroid stimulating hormone levels to be lower in the infants exposed to levonorgestrel than in control infants.
IUDs that released levonorgestrel were inserted 6 weeks after delivery. IUDs released 10 mcg per day (n = 30) or 30 mcg per day (n = 40); copper-releasing IUDs (n = 40) were used as controls. No differences were seen in infant height, weight, development, respiratory infections or blood chemistries up to 12 months of age between the levonorgestrel and copper IUD groups.
Three hundred twenty lactating women were randomized to either an IUD containing levonorgestrel (Mirena; n = 163) or the copper-containing IUD Cu T380A group (n = 157). Follow-up of infants for 1 year found no differences in growth and development or in duration of breastfeeding.
◉ Effects on Lactation and Breastmilk
IUDs releasing levonorgestrel were inserted 6 weeks after delivery. IUDs released 10 mcg per day (n = 30) or 30 mcg per day (n = 40); copper-releasing IUDs (n = 40) were used as controls. The rate of breastfeeding discontinuation was higher with the levonorgestrel groups than in the copper IUD group at 75 days, but not at other times.
In a small prospective study, forty-six women were randomized to have an IUD containing levonorgestrel (Mirena) inserted either within 10 minutes after placental delivery (n = 15), between 10 minutes and 48 hours after placental delivery (n = 15), or after 6 weeks postpartum (n = 16). At 6 months postpartum, no statistical difference in the rates of continued breastfeeding (extent not stated) was found among the groups.
Women who gave birth were offered contraception with a levonorgestrel-containing IUD and randomized to have the IUD placed immediately following delivery (n = 46) or at 6 to 8 weeks postpartum (n = 50). Women randomized to later IUD insertion were more likely to be nursing at 6 months postpartum (24% vs 6%) and tended to have a longer median duration of exclusive breastfeeding.
A noninferiority trial compared breastfeeding in women who received a levonorgestrel IUD (product and dose not specified) immediately postpartum (n = 132) or at 8 weeks postpartum (n = 127). At 8 weeks, women who received the IUD immediately postpartum had a 5% lower rate of any breastfeeding (79% vs 84%), which fell withing the predetermined 15% noninferiority margin. Exclusive breastfeeding was slightly lower at 8 weeks in the immediate group (33% vs 40%), but the difference was not statistically significant. The time to lactogenesis in the immediate group was noninferior to that of the delayed group (65.3 vs 63.6 hours). Twenty-four device expulsions occurred in the immediate group compared to 2 in the delayed group (19% vs 2%), which was statistically significant.
◉ Summary of Use during Lactation
This record contains information specific to the levonorgestrel implant, which is not available in the United States. Although nonhormonal methods are preferred during breastfeeding, progestin-only contraceptives such as levonorgestrel are considered the hormonal contraceptives of choice during lactation. Fair quality evidence indicates that levonorgestrel does not adversely affect the composition of milk, the growth and development of the infant. Expert opinion and a metanalysis hold that the risks of progestin-only contraceptive products usually are acceptable for nursing mothers at any time postpartum. Limited, low quality evidence indicates that there is no difference in breastfeeding rates at 6 and 12 months between immediate and delayed insertion of progestin-containing contraceptive implants. Some evidence indicates that progestin-only contraceptives may offer protection against bone mineral density loss during lactation, or at least do not exacerbate it.
◉ Effects in Breastfed Infants
Numerous studies have found no systematic differences in growth, development or illness rates between the infants of mothers who received Norplant as a contraceptive and those of other mothers receiving either no contraception or nonhormonal contraception. One study found serum thyroid stimulating hormone levels to be lower in the infants exposed to levonorgestrel than in control infants.
Ten women received Norplant-2 beginning at 4 weeks postpartum. Mothers collected 4-hour urine samples daily from weeks 4 to 11 postpartum from their infants. Urine samples were analyzed for follicle-stimulating hormone, luteinizing hormone and testosterone. No difference was found in these levels when compared to those of infants whose mothers were taking either no contraception or an oral progestin-only contraceptive containing 30 mcg of levonorgestrel.
Multicenter, nonrandomized studies followed infants whose mothers received levonorgestrel contraception during breastfeeding, either as oral tablets of 37.5 mcg daily (n = 246) or as Norplant (n = 453). No adverse effects on infant growth through the first year were found in comparison to standard measurements. In a continuation study, infants from these studies who were exposed to levonorgestrel via Norplant (total n = 220) were followed up to 6 years of age. Infants were fully breastfed for an average of 7.8 months and were breastfed at least once daily for an average of 16.5 months. No differences in growth, diseases, surgery or hospitalizations were found from years 2 through 6 between infants whose mothers used levonorgestrel implants or Copper T IUD. An increase in skin conditions occurred in the levonorgestrel group and an increase in urogenital conditions occurred in the Copper T group.
◉ Effects on Lactation and Breastmilk
Numerous studies of varying size and quality have found that the use of levonorgestrel implants (Norplant or Norplant-2) as a contraceptive beginning at 7 days postpartum or later either has no clinically important negative effect on the quality of breastmilk and results in either no effect or an increase in the milk supply and duration of lactation.
In a nonrandomized study, 100 women who received Norplant implants at an average of day 55 postpartum were compared to 100 women receiving a postpartum IUD. No differences were found between the control and Norplant groups in the number of women nursing at days 10 and 20 and months 1 to 12 postinsertion except a slight decrease in the number of mothers using Norplant who were exclusively breastfeeding at 12 months. No difference since the time of weaning was noted between the groups.
A secondary analysis of a study in Uganda examined 96 postpartum women randomized to receive a 2-rod levonorgestrel implant (Jadelle, Bayer AG, Berlin) either within 5 days of birth (n = 55) or at 6 to 8 weeks postpartum (n = 42). No differences were found between the groups in infant growth from birth to 6 months, time to lactogenesis II, or proportion of mothers breastfeeding at 3 and 6 months.
A study in Malawi compared the breastfeeding rates between women who received an etonogestrel (n = 28) or levonorgestrel (n= 112) implant immediately postpartum. Mothers chose the method and were followed for 2 years postpartum. Most women breastfed for 2 years. No difference was seen in the exclusive breastfeeding rate at 6 months between the groups nor in the continuation of breastfeeding to 2 years.
◉ Summary of Use during Lactation
This record contains information specific to oral levonorgestrel used alone for contraception. Those with an interest in a combination oral contraceptive should consult the record entitled, Contraceptives, Oral, Combined.
Although nonhormonal methods are preferred during breastfeeding, progestin-only contraceptives such as levonorgestrel are considered the hormonal contraceptives of choice during lactation. Fair quality evidence indicates that levonorgestrel does not adversely affect the composition of milk, the growth and development of the infant or the milk supply. Expert opinion holds that the risks of progestin-only contraceptive products usually are acceptable for nursing mothers at any time postpartum. Some evidence indicates that progestin-only contraceptives may offer protection against bone mineral density loss during lactation, or at least do not exacerbate it. A large percentage of women who planned to breastfeed discontinued oral progestin-only contraceptives by 3 months postpartum and progestin-only contraceptives often result in rapid repeat pregnancy. Postcoital levonorgestrel appears to have no long-term adverse effects on breastfeeding or the infant.
◉ Effects in Breastfed Infants
One study found serum thyroid stimulating hormone levels to be lower in the infants exposed to levonorgestrel than in control infants.
A nonrandomized trial compared 250 breastfed infants whose mothers received 30 mcg daily of oral levonorgestrel initiated 7 days postpartum to 250 infants whose mothers received nonhormonal contraception. No differences in height and weight gain were seen during the 9-month study period between the 2 groups.
Multicenter, nonrandomized studies followed infants whose mothers received levonorgestrel contraception during breastfeeding, either as oral tablets of 37.5 mcg daily (n = 246) or as Norplant (n = 453). No adverse effects on infant growth through the first year were found in comparison to standard measurements.
In a cohort study of 71 nursing women who took levonorgestrel as a postcoital contraceptive, none noticed any adverse effect in their infants.
In a cohort study, breastfed infants of women (n = 100) who used at least one dose of levonorgestrel as a postcoital contraceptive in addition to the lactational-amenorrhea method (LAM) of birth control were compared to infants whose mothers used LAM only (n = 100). No statistically significant differences were found between the groups in weight, length, head circumference, chest circumference, and mid-arm circumference at 3 and 6 months postpartum, nor in the Denver Developmental Screening Test results at 6 months postpartum.
◉ Effects on Lactation and Breastmilk
Among a cohort study of 71 women who took levonorgestrel as a postcoital contraceptive during nursing, none reported any obvious decrease in milk supply after the drug was used.
A study of 1158 postpartum randomized women using the lactational amenorrhea method (LAM) for birth control randomized to be given levonorgestrel as a postcoital contraceptive or given nothing. No difference in the duration of breastfeeding was found between women who used the levonorgestrel and those who did not.
In a nonrandomized, nonblinded study comparing women who were breastfeeding at discharge, 102 postpartum women received depot medroxyprogesterone acetate (dosage not stated) in the early postpartum period (average 51.9 hours postpartum; range 6.25 to 132 hours), 181 received another progestin-only contraceptive and 138 used nonhormonal contraception. No differences in breastfeeding rates were seen at 2 and 6 weeks, but women receiving any hormonal contraceptive were breastfeeding at a lower rate (72.1% vs 77.6%) at 4 weeks postpartum. The authors concluded that progestin-only contraception initiated in the early postpartum period had no adverse effects on breastfeeding rates.
A study analyzed data from a prospective cohort study of U.S. women from May 2005 through June 2007. Women were followed from the third trimester of pregnancy throughout the first year postpartum. Data from the subset of women who professed that intended to breastfeed for 3 months or longer postpartum during their third trimester of pregnancy and who were using a contraceptive at 3 months postpartum were analyzed (n = 1349). Women who intended to breastfeed for at least 4 months and were taking a progestin-only oral contraceptive, such as levonorgestrel, were 3.15 times more likely to be breastfeeding (exclusive or nonexclusive) at 4 months than women who used a nonhormonal contraceptive. Women who said they would breastfeed for 3 to 4 months had 4-month breastfeeding rates equivalent to those using a nonhormonal contraceptive. These rates were much higher than those of women who were taking an estrogen-containing, combined oral contraceptive.
In a cohort study, women (n = 100) who used at least one dose of levonorgestrel as a postcoital contraceptive in addition to the lactational-amenorrhea method (LAM) of birth control were compared to mothers used LAM only (n = 100). No difference was found in the mothers' subjective opinions of their milk supplies.
- Take at the same time every day.
- Take with or without food. The effect of food on absorption has not been evaluated.
- PubChem
- Australian Industrial Chemicals Introduction Scheme (AICIS)18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17.alpha.)-https://services.industrialchemicals.gov.au/search-assessments/
- ChemIDplusLevonorgestrel [USAN:USP:INN:BAN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0000797637
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useLevonorgestrelhttps://www.drugbank.ca/drugs/DB00367
- DTP/NCILICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuse
- EPA DSSToxLevonorgestrelhttps://comptox.epa.gov/dashboard/DTXSID3036496
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-noticeLevonorgestrel (EC: 212-349-8)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/97639
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Hazardous Substances Data Bank (HSDB)LEVONORGESTRELhttps://pubchem.ncbi.nlm.nih.gov/source/hsdb/6483
- California Safe Cosmetics Program (CSCP) Product DatabaseLevonorgestrel implantshttps://www.cdph.ca.gov/Programs/CCDPHP/DEODC/OHB/CSCP/Pages/About-CSCP.aspx
- DailyMed
- Drug Induced Liver Injury Rank (DILIrank) DatasetLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuse
- European Medicines Agency (EMA)LICENSEInformation on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.https://www.ema.europa.eu/en/about-us/legal-noticelevonorgestrel (P/0447/2022)https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002474-pip02-18-m01levonorgestrel (P/75/2010)https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/levonorgestrel
- Drugs and Lactation Database (LactMed)Intrauterine Levonorgestrelhttps://www.ncbi.nlm.nih.gov/books/n/lactmed/LM1335/Levonorgestrel Implanthttps://www.ncbi.nlm.nih.gov/books/n/lactmed/LM1336/Oral Levonorgestrelhttps://www.ncbi.nlm.nih.gov/books/n/lactmed/LM421/
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingLEVONORGESTRELhttps://www.accessdata.fda.gov/scripts/cder/daf/
- FDA Orange BookLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Japan Chemical Substance Dictionary (Nikkaji)
- MassBank of North America (MoNA)LICENSEThe content of the MoNA database is licensed under CC BY 4.0.https://mona.fiehnlab.ucdavis.edu/documentation/license
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.htmllevonorgestrelhttps://rxnav.nlm.nih.gov/id/rxnorm/6373
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/aboutlevonorgestrelhttps://pharos.nih.gov/ligands/DHGCDXWV45Y1
- Springer Nature
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/Levonorgestrelhttps://www.whocc.no/atc_ddd_index/?code=G03AC03Levonorgestrelhttps://www.whocc.no/atc_ddd_index/?code=G03AD01
- WHO Model Lists of Essential MedicinesLICENSEPermission from WHO is not required for the use of WHO materials issued under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Intergovernmental Organization (CC BY-NC-SA 3.0 IGO) license.https://www.who.int/about/policies/publishing/copyrightLevonorgestrelhttps://list.essentialmeds.org/medicines/186
- WikipediaCytarabinehttps://en.wikipedia.org/wiki/Cytarabine